P48736 (PK3CG_HUMAN) Homo sapiens (Human)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform UniProtKBInterProSTRINGInteractive Modelling
1102 aa; Sequence (Fasta)
It is possible new templates exist for this target since these models were created.
Available Structures
105 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Structure of p110 gamma bound to the Ras inhibitory nanobody NB7 |
Heteromer | |||||
| Assess | ||||||
| Structure of the phosphoinositide 3-kinase p110 gamma (PIK3CG) p101 (PIK3R5) complex |
Heteromer O02696; | |||||
| Assess | ||||||
| Ras G12V - PI 3-kinase gamma complex |
Heteromer P01112; | 1×MG; 1×GNP; | ||||
| Assess | ||||||
| Structure of Pi3K gamma with a potent inhibitor: GSK2126458 | homo-2-mer | 4×SO4; 2×ZIG; | ||||
| Assess | ||||||
| 3-Quinoline Carboxamides inhibitors of Pi3K | monomer | 1×3QH; 1×SO4; | ||||
| Assess | ||||||
| Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-Dihydro-2H-benzo[1,4]oxazines | monomer | 1×41A; | ||||
| Assess | ||||||
| Selective small molecule inhibitor discovered by chemoproteomic assay platform reveals regulation o… | monomer | 1×7L0; | ||||
| Assess | ||||||
| A pharmacological map of the PI3-K family defines a role for p110alpha in signaling: The structure … | monomer | 1×090; | ||||
| Assess | ||||||
| complex of human phosphoinositide 3-kinase catalytic subunit gamma (p110 gamma) with PIK-284 | monomer | 1×ABJ; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with CH5132799 | monomer | 1×MMD; 2×SO4; | ||||
| Assess | ||||||
| Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04691502 through Structure Based Drug De… | monomer | 1×ML9; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with CH5108134 | monomer | 1×MMY; 2×SO4; | ||||
| Assess | ||||||
| Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors. | monomer | 1×3PS; | ||||
| Assess | ||||||
| Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors. | monomer | 1×3RZ; | ||||
| Assess | ||||||
| A pharmacological map of the PI3-K family defines a role for p110alpha in signaling: The structure … | monomer | 1×093; | ||||
| Assess | ||||||
| Potent and Selective Inhibitors of PI3K-delta: Obtaining Isoform Selectivity from the Affinity Pock… | monomer | 1×0SC; | ||||
| Assess | ||||||
| Design and Synthesis of a Novel Pyrrolidinyl Pyrido Pyrimidinone Derivative as a Potent Inhibitor o… | monomer | 1×0TB; | ||||
| Assess | ||||||
| Crystal Structure of PI3K gamma with N6-(3,4-dimethoxyphenyl)-2-morpholino-[4,5'-bipyrimidine]-2',6… | monomer | 1×13K; 1×SO4; | ||||
| Assess | ||||||
| Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04691502 through Structure Based Drug De… | monomer | 1×ML8; | ||||
| Assess | ||||||
| 4-Methylpteridineones as Orally Active and Selective PI3K/mTOR Dual Inhibitors | monomer | 1×OAW; | ||||
| Assess | ||||||
| Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors. | monomer | 1×3RE; | ||||
| Assess | ||||||
| Potent and Selective Inhibitors of PI3K-delta: Obtaining Isoform Selectivity from the Affinity Pock… | monomer | 1×0SE; | ||||
| Assess | ||||||
| Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, … | monomer | |||||
| Assess | ||||||
| Structure determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, … | monomer | 1×STU; | ||||
| Assess | ||||||
| Complex of PI3K gamma with an inhibitor | monomer | 1×NPZ; | ||||
| Assess | ||||||
| Fragment Bound to PI3Kinase gamma | monomer | 1×XAZ; | ||||
| Assess | ||||||
| Structure of PI3K gamma in complex with an inhibitor | monomer | 1×456; | ||||
| Assess | ||||||
| A pharmacological map of the PI3-K family defines a role for p110 alpha in signaling: The structure… | monomer | 1×039; | ||||
| Assess | ||||||
| Structure of PI3K gamma in complex with N-[6-(pyridin-3-yl)-1,3-benzothiazol-2-yl]acetamide | monomer | 1×2WJ; | ||||
| Assess | ||||||
| Design and Synthesis of a Novel Pyrrolidinyl Pyrido Pyrimidinone Derivative as a Potent Inhibitor o… | monomer | 1×0TA; | ||||
| Assess | ||||||
| Crystal Structure of human PI3Kgamma complexed with AS605240 | monomer | 1×QYT; | ||||
| Assess | ||||||
| Structure of PI3K gamma in complex with an inhibitor | monomer | 1×43R; | ||||
| Assess | ||||||
| Crystal Structure of a Pyrazolopyrimidine Inhibitor Bound to PI3 Kinase Gamma | monomer | 1×SO4; 1×L64; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with CH5039699 | monomer | 2×SO4; 1×BMW; | ||||
| Assess | ||||||
| Structure of PI3K gamma with Imidazopyridine inhibitors | monomer | 1×1UJ; 1×SO4; | ||||
| Assess | ||||||
| Structure of PI3K gamma in complex with 1-[6-(5-methoxypyridin-3-yl)-1,3-benzothiazol-2-yl]-3-[2-(1… | monomer | 1×2WH; | ||||
| Assess | ||||||
| Structure of PI3K gamma in complex with N-[6-(5,6-dimethoxypyridin-3-yl)-1,3-benzothiazol-2-yl]acet… | monomer | 1×2WK; | ||||
| Assess | ||||||
| Crystal Structure of PI3K gamma with 3-(2-morpholino-6-(pyridin-3-ylamino)pyrimidin-4-yl)phenol | monomer | 1×P2B; | ||||
| Assess | ||||||
| Crystal Structure of PI3K gamma with 5-(2,4-dimorpholinopyrimidin-6-yl)-4-(trifluoromethyl)pyridin-… | monomer | 1×SD5; | ||||
| Assess | ||||||
| Structure of PI3K gamma with Imidazopyridine inhibitors | monomer | 1×1UK; 1×SO4; | ||||
| Assess | ||||||
| PI3K-gamma K802T in complex with Cpd 8 10-((1-(tert-butyl)piperidin-4-yl)sulfinyl)-2-(1-isopropyl-1… | monomer | 1×BWY; | ||||
| Assess | ||||||
| Structure of Pi3K gamma with inhibitor | monomer | 1×SO4; 1×LXX; | ||||
| Assess | ||||||
| Potent and Highly Selective Benzimidazole Inhibitors of PI3K-delta | monomer | 1×0WR; | ||||
| Assess | ||||||
| PI3 Kinase Gamma bound to a pyrmidine inhibitor | monomer | 1×0VU; | ||||
| Assess | ||||||
| Structure of Phosphoinositide 3-kinase gamma (PI3K) bound to the potent inhibitor PIKin3 | monomer | 1×6K5; 1×SO4; | ||||
| Assess | ||||||
| Structure-based design of thienobenzoxepin inhibitors of PI3- kinase | monomer | 1×FAV; | ||||
| Assess | ||||||
| Rational Design of PI3K-alpha Inhibitors that Exhibit Selectivity Over the PI3K-beta Isoform | monomer | 1×3T8; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with AMG511 | monomer | 4×SO4; 1×14K; | ||||
| Assess | ||||||
| Crystal Structure of PI3K-gamma in Complex with Imidazopyridine 2 | monomer | 4×SO4; 1×0TZ; | ||||
| Assess | ||||||
| Crystal structure of PI3Kgamma in complex with DNA-PK inhibitor AZD7648 | monomer | 1×MBW; | ||||
| Assess | ||||||
| X-ray structure of PI3Kinase Gamma in complex with Copanlisib | monomer | 1×6E2; 1×SO4; | ||||
| Assess | ||||||
| Crystal structure of PI3Kgamma with a dihydropurinone inhibitor (compound 18) | monomer | 1×IGJ; | ||||
| Assess | ||||||
| Discovery of GDC-0980: a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kin… | monomer | 1×980; | ||||
| Assess | ||||||
| Structure of PI3K gamma in complex with GDC0941 | monomer | 1×GD9; | ||||
| Assess | ||||||
| Potent and Selective Inhibitors of PI3K-delta: Obtaining Isoform Selectivity from the Affinity Pock… | monomer | 1×0SD; | ||||
| Assess | ||||||
| Phosphoinositide 3-Kinase gamma bound to a thiazole inhibitor | monomer | 1×WJV; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with Compound 4 | monomer | 1×V81; 2×SO4; | ||||
| Assess | ||||||
| PI3Kg in complex with AZD6482 | monomer | 1×A82; | ||||
| Assess | ||||||
| Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-… | monomer | 1×JZX; | ||||
| Assess | ||||||
| Structure-based design of thienobenzoxepin inhibitors of PI3-Kinase | monomer | 1×FAZ; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with Compound 17 | monomer | 1×V84; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with inhibitor IPI-549 | monomer | 1×V7Y; 2×SO4; | ||||
| Assess | ||||||
| Crystal Structures of Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors | monomer | 1×JZW; | ||||
| Assess | ||||||
| Crystal Structure of PI3K-gamma in Complex with Imidazopyridazine 19e | monomer | 4×SO4; 1×0U0; | ||||
| Assess | ||||||
| Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-… | monomer | 1×JZY; | ||||
| Assess | ||||||
| Phosphoinositide 3-Kinase gamma bound to an pyrrolopyridinone Inhibitor | monomer | 1×EFV; 4×SO4; | ||||
| Assess | ||||||
| Catalytic unit of PI3Kg in complex with PI3K/mTOR dual inhibitor PF-04979064 | monomer | 1×19P; | ||||
| Assess | ||||||
| PI3-kinase-gamma with a pyrrolopyridine-benzofuran inhibitor | monomer | 2×SO4; 1×WYE; | ||||
| Assess | ||||||
| Structure-based Optimization of Pyrazolo -Pyrimidine and -Pyridine Inhibitors of PI3-Kinase | monomer | 1×NZU; | ||||
| Assess | ||||||
| IPI-549 bound to the PI3Kg catalytic subunit p110 gamma | monomer | 1×V7Y; | ||||
| Assess | ||||||
| PQR309 - a Potent, Brain-Penetrant, Orally Bioavailable, pan-Class I PI3K/mTOR Inhibitor as Clinica… | monomer | 1×A3W; 2×SO4; | ||||
| Assess | ||||||
| Fragment based discovery of a novel and selective PI3 Kinase inhibitor | monomer | 1×ZW3; | ||||
| Assess | ||||||
| Complexes of PI3Kgamma with isoform selective inhibitors. | monomer | 1×SO4; 1×751; | ||||
| Assess | ||||||
| Gedatolisib bound to the PI3Kg catalytic subunit p110 gamma | monomer | 1×VL1; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with quinoline-containing inhibitor 5g | monomer | 3×SO4; 1×6RF; | ||||
| Assess | ||||||
| Crystal structure of PI3K-gamma in complex with triazine-benzimidazole 32 | monomer | 3×SO4; 1×QAR; | ||||
| Assess | ||||||
| Structure-based Optimization of Pyrazolo -Pyrimidine and -Pyridine Inhibitors of PI3-Kinase | monomer | 1×NZS; | ||||
| Assess | ||||||
| Compound 21 (1-alkyl-substituted 1,2,4-triazoles) | monomer | 1×17V; | ||||
| Assess | ||||||
| Crystal structure of PI3K-gamma in complex with benzothiazole 82 | monomer | 3×SO4; 1×QK0; | ||||
| Assess | ||||||
| PI3 Kinase gamma with a benzofuranone inhibitor | monomer | 1×WYF; | ||||
| Assess | ||||||
| Crystal structure of PI3K-gamma in complex with a quinoline inhibitor | monomer | 3×SO4; 1×2NQ; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3… | monomer | 2×SO4; 1×3VC; | ||||
| Assess | ||||||
| Crystal structure of PI3K p110gamma catalytical domain in complex with organoruthenium inhibitor DW2 | monomer | 1×DW2; | ||||
| Assess | ||||||
| Crystal structure of PI3K-gamma in complex with quinoline-indoline inhibitor 24f | monomer | 3×SO4; 1×FJY; | ||||
| Assess | ||||||
| Crystal structure of PI3K-gamma in complex with triazine-benzimidazole 1 | monomer | 3×SO4; 1×QAQ; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with a pyridyl-triazine inhibitor | monomer | 3×SO4; 1×0KO; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with a pyridyl-triazine-sulfonamide inhibitor | monomer | 6×SO4; 1×F1S; | ||||
| Assess | ||||||
| X-ray structure of PI3K-gamma bound to a 4-(morpholin-4-yl)- (6-oxo-1,6-dihydropyrimidin-2-yl)amide… | monomer | 1×0W7; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with phenylquinoline inhibitor N-{(1S)-1-[8-chloro… | monomer | 4×SO4; 1×3VD; | ||||
| Assess | ||||||
| Complexes of PI3Kgamma with isoform selective inhibitors. | monomer | 1×SO4; 1×O92; | ||||
| Assess | ||||||
| Structure of Phosphoinositide 3-kinase gamma (PI3K) bound to the potent inhibitor PIKin2 | monomer | 1×6K7; 4×SO4; | ||||
| Assess | ||||||
| Complexes of PI3Kgamma with isoform selective inhibitors. | monomer | 1×534; | ||||
| Assess | ||||||
| Complexes of PI3Kgamma with isoform selective inhibitors. | monomer | 1×SO4; 1×EM7; | ||||
| Assess | ||||||
| Crystal Structure of human PI3Kgamma complexed with AS604850 | monomer | 1×BYM; | ||||
| Assess | ||||||
| Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase beta isoform | monomer | 1×1JV; | ||||
| Assess | ||||||
| NVS-PI3-4 bound to the PI3Kg catalytic subunit p110 gamma | monomer | 1×VLV; | ||||
| Assess | ||||||
| Crystal structure of PI3K p110gamma catalytical domain in complex with organoruthenium inhibitor E5… | monomer | 1×E52; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with pyridinylquinoline inhibitor N-{(1S)-1-[8-chl… | monomer | 3×SO4; 1×3VE; 1×GOL; | ||||
| Assess | ||||||
| Crystal structure of PI3K-gamma in complex with benzothiazole 1 | monomer | 1×QJZ; 1×SO4; | ||||
| Assess | ||||||
| PI3Kg IN COMPLEX WITH 5d | monomer | 1×74F; | ||||
| Assess | ||||||
| Crystal structure of human PI3K-gamma in complex with benzimidazole inhibitor 5 | monomer | 3×SO4; 1×5MT; | ||||
| Assess | ||||||
| PI3Kg IN COMPLEX WITH INH | monomer | 1×DD8; | ||||
| Assess | ||||||
| PI3Kg IN COMPLEX WITH Compound 7 | monomer | 1×DD8; | ||||
| Assess | ||||||
| Crystal structure of PI3K-gamma in complex with pyrrolo-pyridine inhibitor 63 | monomer | 4×SO4; 1×4FJ; | ||||
| Assess | ||||||
| Crystal structure of PI3Kgamma with a dihydropurinone inhibitor (compound 4) | monomer | 1×M9T; | ||||
| Assess | ||||||
3 SWISS-MODEL models
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 8so9.1.A | monomer | 0.83 | 95.28 | |||
| Assess | ||||||
| 8so9.1.A | monomer | 0.83 | 95.28 | |||
| Assess | ||||||
| 8so9.1.A | monomer | 0.83 | 95.28 | |||
| Assess | ||||||